Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 13/20 | 0.72 |
| ▸ | PIK3CA | P42336 | 12/20 | 0.53 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.47 |
| ▸ | ATR | Q13535 | 3/20 | 0.47 |
| ▸ | ABL1 | P00519 | 3/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1358574 | 0.94 | MTOR (0.72) | MTORPIK3CAPIK3CGATRPIK3CD | |
| SCHEMBL1358651 | 0.84 | MTOR (0.72) | MTORPIK3CAPIK3CGATRPIK3CD | |
| SCHEMBL14776742 | 0.84 | MTOR (1.00) | MTORPIK3CAPIK3CGATRPIK3CD | |
| SCHEMBL1360518 | 0.83 | PIK3CA (0.57) | MTORPIK3CAPIK3CGPIK3CDPIK3CB | |
| SCHEMBL1358955 | 0.83 | MTOR (0.72) | MTORPIK3CAPIK3CGATRPIK3CD | |
| SCHEMBL1358933 | 0.82 | MTOR (0.69) | MTORPIK3CAPIK3CGATRPIK3CD | |
| SCHEMBL1359099 | 0.82 | MTOR (0.79) | MTORPIK3CAPIK3CGATRPIK3CD | |
| SCHEMBL2578221 | 0.80 | MTOR (0.69) | MTORPIK3CAPIK3CGATRPIK3CD | |
| SCHEMBL14776663 | 0.80 | MTOR (0.91) | MTORPIK3CAPIK3CGATRPIK3CD | |
| SCHEMBL16684448 | 0.80 | MTOR (0.70) | MTORPIK3CAPIK3CGATRPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2382207-B1 | PI3K/MTOR KINASE INHIBITORS | XCOVERY HOLDING CO LLC (US) | 2015-04-29 | — | — | EP | claimed |
| US-8586582-B2 | PI3K/mTOR kinase inhibitors | XCOVERY HOLDING COMPANY, LLC (US) | 2013-11-19 | — | — | US | claimed |
| US-20110281857-A1 | PI3K/MTOR KINASE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2011-11-17 | — | — | US | claimed |
| EP-2382207-A2 | PI3K/MTOR KINASE INHIBITORS | Xcovery Holding Company LLC (US) | 2011-11-02 | — | — | EP | claimed |
| WO-2010056320-A2 | PI3K/MTOR KINASE INHIBITORS | TYROGENEX, INC. (US) | 2010-05-20 | — | — | WO | claimed |
| EP-2382207-B1 | PI3K/MTOR KINASE INHIBITORS | XCOVERY HOLDING CO LLC (US) | 2015-04-29 | — | — | EP | disclosed |
| EP-2382207-B1 | PI3K/MTOR KINASE INHIBITORS | XCOVERY HOLDING CO LLC (US) | 2015-04-29 | — | — | EP | disclosed |
| US-8586582-B2 | PI3K/mTOR kinase inhibitors | XCOVERY HOLDING COMPANY, LLC (US) | 2013-11-19 | — | — | US | disclosed |
| US-8586582-B2 | PI3K/mTOR kinase inhibitors | XCOVERY HOLDING COMPANY, LLC (US) | 2013-11-19 | — | — | US | disclosed |
| US-8586582-B2 | PI3K/mTOR kinase inhibitors | XCOVERY HOLDING COMPANY, LLC (US) | 2013-11-19 | — | — | US | disclosed |
| US-20110281857-A1 | PI3K/MTOR KINASE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110281857-A1 | PI3K/MTOR KINASE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110281857-A1 | PI3K/MTOR KINASE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2011-11-17 | — | — | US | disclosed |
| WO-2010056320-A2 | PI3K/MTOR KINASE INHIBITORS | TYROGENEX, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281857-A1 | PI3K/MTOR KINASE INHIBITORS | MTOR, PIK3CA, PI4KA | MTOR 1/4885PIK3CA 2/4885PIK3CG 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.